Purdue Pharma researches, develops, and manufactures prescription and over-the-counter medicines. Products include treatments for chronic and severe pain, including OxyContin, a controlled-release version of oxycodone; HysinglaER, an extended-release hydrocodone drug; and buprenorphine pain patch Butrans. It is also developing opioid addiction therapies and treatments for cancers, ADHD, nervous system disorders, and pain. The company filed for bankruptcy protection in 2019 after facing extensive scrutiny over its opioid-marketing practices. Through the restructuring, the company will convert into a new public-benefit entity.
See detailed business credit reports on other businesses or your own.
See detailed profiles for insights and prospects on this company's top competitors.
Get in Touch with 8 Principals*
STEVE MILLERChairman of the Board
CRAIG LANDAUPresident and Chief Executive Officer
EDWARD B MAHONYChief Financial Officer